Supriya Lifescience Limited
Against an issue price of ₹274. Split- and bonus-adjusted official closes — a past move, never a forecast.
Supriya Lifescience Limited was a mainboard initial public offer.
The book was open from 16 December 2021 to 20 December 2021.
The issue was priced at ₹274 a share, from a band of ₹265 to ₹274.
We did not poll this issue while its book was open. The exchange publishes only the current cumulative figure and no history, so a subscription series cannot be reconstructed after an issue closes.
The shares listed on 28 December 2021.
The last official close on file is ₹931 (1 October 2026), which is 239.8% above the issue price.
It now trades as SUPRIYA, and its filed financials are on its company page.
Shares sold in the issue at ₹274 last closed at ₹931.
See SUPRIYA’s filed financials and price history →Official exchange closes, restated for splits, bonuses and rights issues since listing. A record of past price movement, not a forecast.
- Registrar
- Link Intime India Private Limited
- Lead managers
- ICICI Securities Limited
- Axis Capital Limited
- Bidding opens16 Dec 2021
- Bidding closes20 Dec 2021
- Basis of allotmentnot published
Not published in the exchange feeds we ingest — we do not estimate it.
- Listing28 Dec 2021
We did not poll this issue while its book was open. The exchange publishes only the current cumulative figure and no history, so a subscription series cannot be reconstructed after an issue closes.
We did not poll this issue while its book was open. The exchange publishes only the current cumulative figure and no history, so a subscription series cannot be reconstructed after an issue closes.
We have not extracted an anchor allotment list for this issue.
- All other pre-issue capitalSEBI ICDR 2018 Reg. 17 — all other pre-issue capital, 6 months from allotment28 Jun 2022already free
- Promoters' minimum contributionSEBI ICDR 2018 Reg. 16(1)(a) — promoters' minimum contribution, 18 months from allotment28 Jun 2023already free
Computed from the SEBI ICDR 2018 lock-in rules, not disclosed by the issuer or the exchange. The regulation counts from the date of allotment, which no feed we ingest publishes, so these are counted from the listing date and fall at most two to three business days later than the true expiry.
Every offer document must set out the reasoning behind its own price: what the company earned in the years before it came to market, and what multiple of those earnings it is asking for. This is that chapter — the issuer’s argument for its price, not our assessment of it.
Weighted-average return on net worth over the same years: 46.43%.
Figures as printed in the offer document's "Basis for Offer Price" chapter. A record of the case the issuer made for its own price, not our valuation of it.
Everything we extracted from this issue's offer document is the pricing justification rather than the restated statements — it is shown under how the offer was priced. The restated financial statements themselves have not been extracted for this issue.
We have not extracted this section from the offer document for this issue yet. It is read from the abridged prospectus, and several offer documents are served as .zip archives or as scanned pages with no text layer.
The offer document must name the listed companies the issuer considers comparable, and print their valuation figures beside its own. This is that list — the issuer’s choice of comparison, not ours.
| Company | P/E | P/B | RoNW | EPS | Income |
|---|---|---|---|---|---|
| Aarti Drugs Limited | 16.8 | 5.2 | 30.7% | 30.09 | ₹21,593 cr |
| Divi's Laboratories Limited | 65.3 | 13.9 | 21.4% | 74.75 | ₹70,320 cr |
| Neuland Laboratories Limited | 27.8 | 2.9 | 10.3% | 62.85 | ₹9,530 cr |
| Solara Active Pharma Sciences Limited | 18.4 | 2.9 | 13.9% | 69.00 | ₹16,457 cr |
| Wanbury Limited | -13.2 | -1.1 | 8.1% | -5.04 | ₹3,949 cr |
The issuer's own figures as printed at the head of the same table — its claim about itself, on the same basis as its claims about the companies below.
Figures as PRINTED by the issuer in its own offer document. The comparison set is the issuer's choice, not ours.
| Firm | Issues | Typical listing move | Below issue @30d | @90d | @180d |
|---|---|---|---|---|---|
Axis Capital Limited 2021 – 2026 | 86 19 measurable | +13.0% | 5 of 15 | 1 of 5 | 2 of 8 |
ICICI Securities Limited 2021 – 2026 | 87 13 measurable | +16.6% | 5 of 11 | 2 of 5 | 1 of 7 |
| Firm | Issues | Typical listing move | Below issue @30d | @90d | @180d |
|---|---|---|---|---|---|
Link Intime India Private Limited 2021 – 2026 | 176 14 measurable | +10.2% | 3 of 13 | 1 of 9 | 0 of 5 |
A count of what happened to the other issues each firm was named on, computed from exchange closes. Not a rating, not a ranking, and not a view on the firm.
- Prospectus· PDF · exchange archive24 Dec 2021
- Draft red herring prospectus (DRHP)· ZIP · exchange archive15 May 2021
Filed with SEBI and the exchanges by the issuer. These are the source for every figure on this page.
Compiled from NSE and SEBI offer documents and exchange feeds. A description of the issue and of the bids received — not investment advice, and not a view on whether to apply. No grey-market premium, no allotment lookup and no listing-gain estimate is published here.